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Abstract
Background: Morvan syndrome is a rare disorder characterized by the combination of peripheral nerve
hyperexcitability, encephalopathy and dysautonomia with marked insomnia. It was reported to have association to
antibodies to voltage-gated potassium channels including contactin associated protein-like 2 antibodies (CASPR2-Ab)
and leucine-rich glioma inactivated protein 1 antibodies (LGI1-Ab). LGI1-Ab was reported to associate with seizures,
amnesia, confusion, hyponatraemia and a good prognosis, while CASPR2-Ab with peripheral presentations, probable
risk for tumor and a poor prognosis. The vast majority of Morvan syndrome patients were male, with normal magnetic
resonance imaging of the brain.
Case presentation: We report a female case presenting with a combination of bilateral leg pain, widespread
myokymia, memory disturbance, seizure, hyperhidrosis and insomnia. She had antibodies targeting CASPR2 and LGI1,
tested by the indirect immunofluorescence test, which demonstrated the diagnosis of typical Morvan syndrome as
well as classical limbic encephalitis. Cranial MRI revealed bilateral hyper-intensity of the medial temporal lobe, insular
lobe and basal ganglia on T2/FLAIR and DWI sequence. As the treatment carried on, her serum LGI1-Ab disappeared
and her memory loss, seizure and confusion quickly relieved. But her peripheral presentations did not relieve until
serum CASPR2-Ab turned negative. Intravenous immunoglobulin treatment showed limited efficacy while she
achieved almost complete remission with corticosteroids therapy.
Conclusions: This case provides a rare female resource of Morvan syndrome, which is the first patient with both
CASPR2-Ab and LGI1-Ab positive Morvan syndrome in China and one of the few female patients with Morvan
syndrome reported so far. Through the detailed analysis of her clinical course, the diverse and overlapping clinical
phenotype of CASPR2-Ab and LGI1-Ab in patients with Morvan syndrome was obvious and interesting.
Keywords: Morvan syndrome, Leucine-rich glioma inactivated protein 1 antibodies, Contactin associated protein-like 2
antibodies, Limbic encephalitis, Voltage-gated potassium channels
Background
Limbic encephalitis (LE) is defined as the subacute devel-
opment of seizures, short-term memory loss, confusion
and psychiatric symptoms suggesting the involvement of
the limbic system [1]. Peripheral nerve hyperexcitability
(PNH) is used to describe acquired neuromyotonia
(NMT) or partial manifestations of this disorder including
cramps, muscle twitching (fasciculations or myokymia)
and muscle stiffness [2, 3]. And Morvan syndrome is a
rare disorder characterized by the combination of PNH or
NMT, encephalopathy and dysautonomia with marked
insomnia [4]. The vast majority of Morvan syndrome
patients were male, with normal magnetic resonance
imaging (MRI) of the brain [4]. Plenty of studies have
demonstrated the association between Morvan syndrome
and antibodies to voltage-gated potassium channels
(VGKC-Ab) including contactin associated protein-like
2 antibodies (CASPR2-Ab), leucine-rich glioma inacti-
vated protein 1 antibodies (LGI1-Ab) and other anti-
bodies [2, 4–8]. LGI1-Ab was reported to associate
with seizures, amnesia, confusion, hyponatraemia and a
good prognosis, while CASPR2-Ab with peripheral
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presentations, probable risk for tumor and a poor prog-
nosis [2, 4, 9].
Here we report on a both CASPR2-Ab and LGI1-Ab
positive female patient who presented with typical Morvan
syndrome as well as classical LE, which is the first patient
with double antibodies positive Morvan syndrome in
China and one of the few female patients with Morvan
syndrome reported so far. She had an abnormal cranial
MRI, and and achieved almost complete remission with
the treatment of steroids and IVIG. Through the detailed
analysis of her clinical course, we aim to emphasis the
diverse and overlapping clinical phenotype of LGI1-Ab
and CASPR2-Ab in patients with Morvan syndrome.
Case presentation
A 40-year-old Chinese woman presented with a 2-month
history of bilateral leg pain, widespread myokymia, mem-
ory disturbance, seizure, hyperhidrosis and insomnia. Two
months prior to the admission, she developed repeating
pain in bilateral proximal end of lower limbs, accompan-
ied with widespread myokymia, shaking of the toes,
insomnia and hyperhidrosis. One week later, she devel-
oped seizures for three times a day, consisting of eyes on
the turn, froth at the mouth, unresponsiveness and con-
vulsion of bilateral upper limbs. Levetiracetam was started
by the referring doctor, which relieved her seizure soon.
From then on, family members noted her recent memory
loss, confusion and apathy. Cranial MRI (Fig. 1) revealed
bilateral hyper-intensity of the medial temporal lobe,
insular lobe and basal ganglia on T2/FLAIR and DWI
sequence. Electroencephalography (EEG) showed a few
non-specific slow waves in background and occasional ab-
normal sharp waves on occipital lead during wakefulness.
Serum test in a cell based assay showed serum VGKC-
complex proteins (EUROIMMUN, Germany) including
CASPR2-Ab strongly positive (+++) and LGI1-Ab posi-
tive (+), while cerebrospinal fluid (CSF) LGI1-Ab was
weakly positive (±), examined by the indirect immuno-
fluorescence test (IIFT) (Fig. 2). CSF for cells, glucose,
chloride and culture were normal, while CSF protein
was mildly elevated at 0.5 g/L. Blood natrium was nor-
mal. Thyroid function and anti-thyroid antibodies
including Anti-TG and Anti-TPO was negative. Tumor
markers (CEA, AFP, CA125, CA19-9, CA15-3, SCCAg,
NSE, Cyfra211, TPS) and paraneoplastic neuronal anti-
bodies (Hu, Ri, Yo) were all negative, and body CT scan-
ning showed no malignancy. Her mini-mental state
examination (MMSE) was 21/30. Neurologic examin-
ation revealed only myokymia in the limbs, shaking of
the toes, and hyperhidrosis. She has no remarkable past
history, personal history or family history.
VGKC-Ab related limbic encephalitis and Morvan’s
syndrome were presumed diagnosis. She was treated
with intravenous immunoglobulin (IVIG) at a dose of
0.4 g/kg/day for 5 days and continued oral prednisolone
20 mg/day treatment for a month. Carbamazepine 0.1 g
tid was administered instead of levetiracetam to prevent
epilepsy recurrence. Her memory loss and confusion
responded quite well to the immunotherapy, while bilat-
eral leg pain, myokymia, shaking of the toes, insomnia as
well as hyperhidrosis mildly relieved but not disap-
peared. Repeated CSF routine, cells, glucose, chloride,
protein, CASPR2-Ab and LGI1-Ab were within the nor-
mal range. Serum CASPR2-Ab was still positive (+)
while LGIA-Ab turned negative. Electromyography
(EMG) revealed abnormal F wave in bilateral lower limb,
indicating abnormal peripheral nerve excitability. Nerve
conduction velocity showed normal motor and sensory
nerve responses, and somatosensory evoked potential
(SEP) of lower limbs were normal. Methylprednisolone
pulse therapy (1 g for 3 days and 500 mg for 3 days) was
commenced, after which all symptoms above got signifi-
cant remission. Repeated MMSE was 27/30. Repeated
serum CASPR2-Ab turned weakly positive (±). Prednis-
olone 60 mg daily oral treatment was administered sub-
sequently with slow tapering (Fig. 3). She did a good
job in following the treatment plan and showed no spe-
cific adverse reaction. In a 50 days’ follow-up, after
stopping all the drugs for almost 1 week, her repeated
MRI (Fig. 1) were normal and all of her symptoms ex-
perienced complete remission.
Methods
Serum from the patient was qualitatively tested for neuro-
pil antibodies associated with autoimmune encephalitis
including antibodies to glutamate receptors type NMDA,
type AMPA1 and type AMPA2, LGI1, CASPR2 and
GABARB1/B2using the indirect immunofluorescence test
(IIFT) (EUROIMMUN, FA 112d-1005-1, Germany). Cell-
based assays (CBAs) for those antibodies were performed
using EU90 cells (EUROIMMUN) transfected with
cDNAs encoding the relevant proteins. Combinations of
substrates were incubated with patient serum (1:10 dilu-
tion) or undiluted CSF sample. In a second step, the at-
tached antibodies were stained with fluorescein-labelled
anti-human antibodies (EUROIMMUN) and made visible
with a fluorescence microscope. Each slide was devided
into six areas detected for the above-mentioned six anti-
bodies and those areas with no specific fluorescene would
be regard as the control of positive area with specific
fluorescence. Fluorescence intensity level was used to
describe the intensity of the specific fluorescence as a
numeric value, reaching from “0” or “−” (no specific fluor-
escence) to “5” or “+++++” (extremely strong specific
fluorescence). The deviation in the fluorescence intensity
of the IIFT amounted to no more than ± 1 fluorescence
intensity level for all samples.
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Discussion
There are very few female Morvan syndrome cases
with both CASPR2-Ab and LGI1-Ab positive [1, 7, 10].
Loukaides et al. [8] have reported a 67-year-old man with
autoantibodies targeting LGI1, CASPR2 and Contactin-2/
Tag-1 presenting with Morvan syndrome. Klein et al. [7]
and Lai et al. [9] have reported 9 patients whose CASPR2-
Ab and LGI1-Ab were both positive, but none of them
were diagnosed with Morvan syndrome. Although 29 Mor-
van syndrome cases have been collected by Irani et al. [4],
of which only two patients were female.
Our patient’s symptoms can be devided into following
aspects. Neuropathic pain, widespread myokymia and
shaking of the toes were manifestations of PNH [2, 3].
And epilepsy, recent memory loss, confusion and apathy
were classified as symptoms of limbic encephalitis (LE)
[1, 4, 9]. With hyperhidrosis as dysautonomia and
insomnia, the patient was diagnosised with a typical
Morvan syndrome [4]. Compared with LE, Morvan syn-
drome showed significant less amnesia, confusion or
seizures as the neuropsychiatric manifestations, but
more hallucinations and agitation. Whereas the presence
of neuromyotonia, dysautomia (hyperhidrosis, cardiovas-
cular) and neuropathic pain would help to distinguish
Morvan syndrome from classical LE [4]. In addition,
most Morvan syndrome patients were reported with
normal cranial MRI findings [4, 8]. For this patient, we
would like to attribute the encephalopathic clinical fea-
tures as well as abnormal intensity on cranial MRI to
the common phenomenon of LE. Thus this patient
should be diagnosed with classical LE as well as Morvan
syndrome.
There was a detailed change of the clinical manifest-
ation and titers of antibodies along with the treatment.
In the beginning, her serum CASPR2-Ab was strongly
positive (+++) and LGI1-Ab was positive (+), while CSF
LGI1-Ab was weakly positive (±). After the treatment of
IVIG, both her serum and CSF LGI1-Ab turned nega-
tive, and in the meanwhile her memory loss, confusion
and apathy resolved to some extent. At the same time,
Fig. 1 Cranial MRI of our patient. Diffusion-weighted magnetic resonance imaging (DWI) (a) and the corresponding plane in fluid-attenuated inversion
recovery (FLAIR) (b) showed bilateral hyper-intensity of the medial temporal lobe, insular lobe and basal ganglia (arrows). Repeated MRI were normal
in February 28, 2015. (c, d)
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her serum CASPR2-Ab kept positive, from which we
could conclude that LGI1-Ab was the primarily relevant
antibody for these encephalopathic symptoms. In this
case we can’t arbitrarily contribute the seizure to LGI1-
Ab for the timely treatment with antiepileptic drugs
since the beginning of seizure. After the methylpredniso-
lone pulse therapy, her symptoms of PNH, insomnia and
hyperhidrosis almost disappeared while serum CASPR2-
Ab turned weakly positive. Besides, titer of CASPR2-Ab
was always higher than that of LGI1-Ab, which indicated
the association of CASPR2-Ab with PNH and Morvan
syndrome. This agrees with the different clinical features
of CASPR2-Ab and LGI1-Ab that CASPR2-Ab was in
association with PNH and Morvan syndrome while
LGI1-Ab with memory loss, cognitive impairment and
seizures [2, 6, 7, 9].
The combination of LGI1-Ab and CASPR2-Ab attracted
our attention. Within the 29 Morvan cases reported by
Irani et al. [4], there were 15 patients with both positive
LGI1-Ab and CASPR2-Ab, among which there were three
patients with additional contactin-2 antibodies. Different
antibodies may contribute to the distinct phenotype of
Morvan syndrome. Our case also corresponded with the
condition that Morvan syndrome is usually associated
with high-titer CASPR2-Ab and often accompanied by
lower-titer LGI1-Ab [4]. From her treatment and clinical
course, the diverse and overlapping effects of LGI1-Ab
and CASPR2-Ab in Morvan syndrome were apparent.
Irani et al. [4] have described 29 Morvan syndrome
cases, of which 27 patients were all male. And all five
Morvan syndrome patients reported by Sarosh et al. [6]
were male. Seven of eight patients with positive
CASPR2-Ab collected by Lancaster et al. [2] with or
without Morvan syndrome were male. The striking male
preponderance in patients with Morvan syndrome and
CASPR2-Ab related disease is interesting. In previous
study, CASPR2 mRNA has been found in the prostate
tissue [11] and Morvan syndrome onset was observed
Fig. 2 The immunoreactivity of patient’s serum to CASPR2 and LGI1 proteins. EU90 cells were transfected with cDNAs encoding CASPR2, LGI1
and other four neuropil proteins associated with autoimmune encephalitis (EUROIMMUN, FA 112d-1005-1, Germany), incubated with this patient’s
serum and detected by IIFT. This patient’s serum collected at different time showed different immunoreactivity to CASPR2 (a, d, g) and LGI1 (b, e, h),
and areas with no specific fluorescene to other proteins on the same slide tested at the same time would be regard as control (c, f, i). The patient’s
serum collected on November 26, 2014 showed strong binding to the surface of cells expressing CASPR2 proteins (a) (50x) and moderate binding to
the ones expressing LGI1 proteins (b)(50x). The patient’s serum collected on December 26, 2014 showed moderate binding to the surface of cells
expressing CASPR2 proteins (d) (50x) and no binding to the ones expressing LGI1 proteins (e) (50x). The patient’s serum collected on January 12, 2015
showed weak binding to the surface of cells expressing CASPR2 proteins (g) (100x) and no binding to the ones expressing LGI1 proteins (h) (100x)
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after scrotal drainage in some cases [4]. These might in-
dicated that the storage and release of relevant anti-
bodies in the male productive system increase the titer
of serum antibodies to cause Morvan syndrome [4, 11].
In the contrast, this case would add a valuable female re-
source to the mechanism study of Morvan syndrome
and VGKC antibodies.
Although LGI1-Ab was commonly agreed with no as-
sociation with neoplasm, no agreement on the relation
between CASPR2-Ab and neoplasm has been reached.
Previous studies have shown CASPR2-Ab positive
patients were more likely to be found with neoplasm
especially thymomas, accompanied with acetylcholine
receptor antibodies and myasthenia gravis (MG) [4, 6,
11–13]. And CASPR2 has been reported to function as a
tumor suppressor gene in glioma by Bralten et al. [14].
However, some other studies showed no neoplasm in a
long follow-up in CASPR2-Ab positive patients [2, 9].
And there has been no evidence showing the difference
of neoplasm concurrent rate between both CASPR2-Ab
and LGI1-Ab positive patients and only CASPR2-Ab
positive patients [4, 7]. With a short term follow-up,
there has been no finding showed any neoplasm in this
patient.
Most Morvan syndrome patients without neoplasm
responded well to immunotherapy including IVIG,
plasma exchange and corticosteroids, while patients who
coexist with neoplasm mostly had a poor treatment out-
come or prognosis [2, 4, 6]. In this case report, as for
clinical syndromes, the patient got limited benefit from
the initial IVIG treatment while got significant improve-
ment with methylprednisolone pulse therapy, which was
Fig. 3 Timing of clinical course, antibodies test and treatment. 0, No symptom; +, mild; ++, moderate; +++, severe; IVIG, intravenous immunogloblin;
PED, prednisone; MP, methylprednisolone; LEV, Levetiracetam; CBZ, carbamazepine
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the same with other two cases [8, 15]. However, titres of
CASPR2-Ab significantly reduced while LGI1-Ab turned
negative with IVIG treatment, so the treatment effect of
IVIG should not be overlooked either.
Conclusions
In conclusion, this case provided a rare female case with
typical Morvan syndrome as well as classical LE. It was
showed from the detailed analysis of clinical course that
the combination of LGI1-Ab and CASPR2-Ab might
contribute to distinct phenotype of Morvan syndrome.
With this case, we would like to draw your attention to
the diverse and overlapping effects of these two auto-
antibodies. As to the treatment outcome and risk for
neoplasm, we would have a continuous long follow-up
on this patient.
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